PROLEUKIN (aldesleukin)
INTERLEUKIN 2 · METASTATIC MALIGNANT MELANOMA ·+1
IOVANCE BIOTHER
Drug class
Interleukin 2
Interleukin-2 refers primarily to an endogenous cytokine and a specific biological active ingredient rather than a broad, formal therapeutic drug class, though it represents a foundational category of cytokine-based cancer immunotherapies. Read more about Interleukin 2
2 drugs in this class 2 manufacturers
Drugs in Interleukin 2
LYMPHIR (denileukin diftitox-cxdl)
INTERLEUKIN 2 · CUTANEOUS T-CELL LYMPHOMA
CITIUS PHARMACE
Filter & compare in the drug finder →
Opens the drug finder with Interleukin 2 preselected. Add indication or manufacturer filters there.
Interleukin-2 refers primarily to an endogenous cytokine and a specific biological active ingredient rather than a broad, formal therapeutic drug class, though it represents a foundational category of cytokine-based cancer immunotherapies.
Formulated therapeutically as recombinant human interleukin-2 (such as aldesleukin), it binds cell-surface interleukin-2 receptors to stimulate the proliferation, differentiation, and cytolytic activity of cytotoxic T lymphocytes and natural killer cells.
Recombinant interleukin-2 therapy is primarily indicated for the treatment of adults with metastatic renal cell carcinoma and metastatic melanoma, and it is also utilized to support adoptive cellular immunotherapies.
-
cancer.gov
Interleukin-2 refers primarily to an endogenous cytokine and a specific biological active ingredient rather than a broad, formal therapeutic drug class, though it represents a foundational category of cytokine-based cancer immunotherapies Formulated therapeutically as recombinant human interleukin-2 (such as aldesleukin), it binds cell-surface interleukin-2 receptors to stimulate the proliferation, differentiation, and cytolytic activity of cytotoxic T lymphocytes and natural killer cells Recomb...
-
nih.gov
Interleukin-2 refers primarily to an endogenous cytokine and a specific biological active ingredient rather than a broad, formal therapeutic drug class, though it represents a foundational category of cytokine-based cancer immunotherapies
-
nih.gov
Formulated therapeutically as recombinant human interleukin-2 (such as aldesleukin), it binds cell-surface interleukin-2 receptors to stimulate the proliferation, differentiation, and cytolytic activity of cytotoxic T lymphocytes and natural killer cells
-
clinicaltrials.gov
Formulated therapeutically as recombinant human interleukin-2 (such as aldesleukin), it binds cell-surface interleukin-2 receptors to stimulate the proliferation, differentiation, and cytolytic activity of cytotoxic T lymphocytes and natural killer cells
-
myhealthtoolkitri.com
Recombinant interleukin-2 therapy is primarily indicated for the treatment of adults with metastatic renal cell carcinoma and metastatic melanoma, and it is also utilized to support adoptive cellular immunotherapies
-
cancer.gov
Recombinant interleukin-2 therapy is primarily indicated for the treatment of adults with metastatic renal cell carcinoma and metastatic melanoma, and it is also utilized to support adoptive cellular immunotherapies
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.